Contemporary Reviews in Cardiovascular Medicine Thyroid Replacement Therapy and Heart Failure Anthony Martin Gerdes, PhD; Giorgio Iervasi, MD H eart failure (HF) is a major public health and economic problem in Western countries and is one of the most common causes of hospitalization and death Coronary artery disease is the underlying cause in more than two thirds of chronic HF patients By 2020, the World Health Organization projects that ischemic heart disease alone will be the most important global cause of morbidity and mortality The estimated increases in HF-related morbidity and mortality suggest that our understanding of the pathophysiological mechanisms of this syndrome is inadequate Interest in the role of thyroid hormones (THs) in HF has increased in recent years The driving considerations can be summarized as follows: (1) the known effects of THs on contractile and relaxation properties of the heart; (2) experimental findings offering strong support for the hypothesis that TH signaling is critical in preserving cardiac structure and performance under normal conditions and after cardiac injury; and (3) evidence that mildly altered TH function is strongly associated with a worsening prognosis in cardiac patients in general and in HF patients in particular Diastolic function and systolic function are clearly influenced by THs.1 Ventricular contractile function is also influenced by changes in hemodynamic conditions secondary to TH effects on peripheral vascular tone.1 TH homeostasis preserves positive ventricular-arterial coupling, leading to a favorable balance for cardiac work A study in rats demonstrated that chronic hypothyroidism alone can eventually lead to HF.2 Other studies suggest reduced cardiac tissue triiodothyronine (T3) levels after myocardial infarction (MI) or with development of hypertension by upregulating type deiodinase (D3), which leads to deactivation of T3 and T4 (thyroxine).3– This review highlights a growing body of evidence from animal studies and small-scale clinical trials suggesting that low cellular thyroid activity at the cardiac tissue level may adversely affect HF progression and that treatment may lead to improvement TH Metabolism The human thyroid gland produces and releases hormones mostly as the prohormone T4 In contrast, the thyroid gland secretes just a small amount (4 to ␮g/d) of T3; the major portion (20 to 25 ␮g/d) of T3 derives from conversion of precursor T4.7 Thus, deiodination of T4 in peripheral tissues is the key element of TH metabolism and action because only T3 is considered the biologically active form of the TH Three deiodinase enzymes regulate circulating and tissue concentration of THs: type (D1); type (D2), and type (D3).6 D1 is considered the major peripheral source of circulating T3,8 whereas D2 plays a critical role in providing local conversion to T3 D3 is involved mainly in the conversion of T4 to reverse T3, which is considered an inactive form of TH, and in degrading T3 to inactive diiodothyronine (T2) Cardiac levels of active T3 are dynamically determined by a balance between availability and destruction of T3 Reduced TH function in the heart could arise from or more of the following mechanisms: (1) reduced T3 production and/or increased T3 degradation resulting from inhibition of D1 and D2 activity and/or increased activity of D3, (2) reduced TH uptake and/or increased T3 degradation in the cardiac tissue, (3) changes in TH membrane transporters,9 and (4) altered signaling resulting from changes in TH nuclear receptors TH signaling in cardiac hypertrophy and HF was recently reviewed by Dillmann.10 TH Imbalance and Heart Disease An argument suggesting a link between heart disease and thyroid state is founded on evidence of a relationship between the presence of an altered thyroid state and the occurrence and progression of cardiac disease Maintenance of TH homeostasis is required for proper cardiovascular function Bioactive T3 is a powerful regulator of inotropic and lusitropic properties of the heart through their effects on myosin isoforms and calcium handling proteins in particular.1,11 Hyperthyroidism and hypothyroidism can lead to cardiovascular injury, including HF Development of TH assays permitted differential diagnosis of hypothyroidism from HF in that these diseases share dyspnea, edema, pleural effusions, T-wave changes, a decrease in contractility, decreased cardiac output, and a grossly dilated, flabby heart.12 Hypothyroidism may lead to increased blood cholesterol levels and atherosclerosis.13 Hypothyroidism promotes myocardial fibrosis by stimulating fibroblasts, whereas the opposite is true of hyperthyroidism.14,15 Chronic hypothyroidism in adult rats leads to loss of coronary arterioles, impaired blood flow, a maladaptive change in myocyte shape, and development of HF.2 Changes in cardiac structure and function resulting from hypothyroidism depend only on the severity of TH deficiency and regress with T4 replacement treatment Subclinical (mild) From the Cardiovascular Health Research Center, Sanford Research/University of South Dakota, Sioux Falls (A.M.G.), and Clinical Physiology Institute, CNR/Fondazione G Monasterio CNR–Regione Toscana, Pisa e Massa, Italy (G.I.) Correspondence to A Martin Gerdes, PhD, Cardiovascular Health Research Center, 1100 E 21st St, Suite 700, Sioux Falls, SD 57105 E-mail mgerdes@usd.edu (Circulation 2010;122:385-393.) © 2010 American Heart Association, Inc Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.109.917922 385 Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 386 Circulation July 27, 2010 primary thyroid hypofunction (scHypo or mild hypothyroidism) is defined by elevated values of thyrotropin (TSH) in the presence of normal free T4 (FT4) and total (TT3) or free T3 (FT3) serum concentrations.16,17 All cardiovascular alterations that have been reported in the presence of overt hypothyroidism have also been identified in scHypo, differing only in the extent of the alteration.16 Clinical observations suggest a strong link between scHypo and poor outcome in patients with and without heart disease.18 –24 In particular, many reports suggest that scHypo is a risk factor in heart disease.18,21,25–27 In a recent prospective study of euthyroid HF patients subsequently developing scHypo, a poorer prognosis and increased hospitalization were observed in scHypo patients compared with those with persistent euthyroidism.28 In addition, in chronic HF patients, TSH levels even slightly above normal range are independently associated with a greater likelihood of HF progression.29 Epidemiological data also suggest that scHypo may be the only reversible cause of left ventricular (LV) diastolic dysfunction with slowed myocardial relaxation and impaired filling, particularly in subjects with TSH Ͼ10 ␮IU/mL.16,30 The Health, Aging, Body Composition population-based study showed that participants with TSH Ͼ7 ␮IU/mL had 3-times-higher HF events than euthyroid patients.31 The Cardiovascular Health Study also showed a greater incidence of HF events among participants Ͼ65 years of age with TSH Ͼ10 ␮IU/mL.32 Reports on the prevalence of primary scHypo in the general population vary widely.23,25 The National Health and Nutrition Examination Survey III trial reported that 4.3% of the US population has scHypo, with higher rates in the elderly and women.33 In patients with cardiac diseases, however, the prevalence of primary scHypo is similar to that reported in the general population.18 scHypo is an independent risk factor for atherosclerosis and MI in women24 and is associated with coronary artery disease and increased all-cause mortality in men.25,34 Evidence indicates that patients with clinically stable heart diseases and scHypo have a greater rate of cardiac death than euthyroid patients.18 A randomized crossover trial in patients with scHypo showed beneficial effects of T4 on cardiovascular risk factors and quality of life.26 Results from the Nord-Trøndelag Health Study showed that coronary artery disease mortality in women and unfavorable serum lipids for patients increased at higher TSH levels within the normal range.27,35 Independently from the presence of primary thyroid hypofunction and differently from other organs, the heart is particularly vulnerable to reductions in biologically active T3 in plasma because cardiomyocytes have a negligible capability to generate T3 from locally converted precursor T4 Consequently, when circulating T3 is low, the myocardium may become relatively hypothyroid In animals, a low-T3 state resulting from altered peripheral TH metabolism secondary to caloric restriction is associated with impaired cardiac contractility and changes in cardiac gene expression, similar to those observed during chronic hypothyroidism Importantly, these alterations are reversible after restoration of normal T3 plasma levels by exogenous T3 administration.11 Low-T3 syndrome is the central finding and defines the illness in a variety of acute and chronic severe nonthy- roidal illnesses with cardiac origin, including MI, HF, and surgically treated cardiac disease.1 Low circulating levels of T3 in the absence of primary thyroid hypofunction have been found in 20% to 30% of patients with dilated cardiomyopathy.18 Moreover, FT3 levels were inversely correlated to coronary artery disease, and low T3 levels conferred an adverse prognosis, even after adjustment for coronary risk factors in patients with coronary artery disease, normal LV function, and no history of MI.36 Low-T3 syndrome could be a mere marker of poor health More intriguing, and to the contrary, is the hypothesis that a progressive T3 decrease is part of the vicious pathophysiological circle sustaining cardiac remodeling, neurohumoral activation, and systemic derangement in HF, thus leading to an increase in global and cardiac mortality Consistent with the regulation of many structural and functional genes by T3, a low-T3 state in cardiac tissue may cause impaired diastolic and systolic function, prolongation of action potential, and increased susceptibility to arrhythmias In addition, hypothyroid hearts show poor substrate use such as glucose, lactate, and free fatty acids by mitochondria.37 Accordingly, cardiac oxygen consumption, as measured by positron emission tomography 11 C acetate, was reduced in hypothyroid patients, but cardiac work was compromised more severely than oxidative metabolism This led to decreased cardiac energetic efficiency of the hypothyroid human heart.38 Because of well-known multiple and systemic actions, THs may also interact with other hormone/organ systems and with all the hemodynamic and metabolic variables involved in HF that modulate the development and progression of HF (Figure 1) At present, the concept that altered TH metabolism may contribute to human HF progression is supported mainly by several clinical observational studies showing the important role of a low-T3 state in the prognostic stratification of patients with HF (Table 120,22,39 – 41) Independently of the parameter used, all of these studies showed that impaired T4-to-T3 conversion is associated with a high incidence of fatal events consisting of cardiac or cumulative death or of heart transplantation Impairment of T4-to-T3 conversion was also found to be proportional to the clinical severity of HF as assessed by the New York Heart Association functional classification.21,42 Furthermore, T3 levels in plasma strongly correlated with exercise capacity and oxygen consumption in HF patients.43 In summary, clinical observations seem to indicate the presence of a close pathophysiological link between primary scHypo or impaired T4 to T3 conversion and evolution of HF It is important that clinicians and scientists evaluate the evidence fairly and objectively before making a decision on the potential for therapeutic TH treatment of heart disease This is particularly true because there have been few promising new pharmacological treatment options for HF in recent years TH Metabolism During the Early Post-MI Phase Human and animal studies suggest that low TH levels contribute to worsening outcome after MI There is rapid decline in T3 and TSH during the first week after an acute MI in patients.44 Values for reverse T3 were increased but T4 remained normal Inhospital and postdischarge mortality was highest among patients Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 Gerdes and Iervasi Thyroid Treatment of Heart Failure 387 Figure Thyroid function and HF progression: the vicious pathophysiological circle GFR indicates glomerular filtration rate; GTB, glomerular tubular balance; NE, neuroendocrine; and NP, natriuretic peptides with the most pronounced T3 depression and reverse T3 elevation.19 Moreover, there is a worsening prognosis in post-MI patients with persistently low plasma T3.44 These observations, together with recent evidence that mild TSH abnormalities are associated not only with traditional coronary risk factors35 but Table also with mortality for coronary artery disease,35 support the hypothesis that even a mild reduction in TH levels plays an important role in the myocardial response to acute ischemia Induction of MI in severely hypothyroid dogs led to a dramatic increase in infarct size.45 Ojamaa et al46 demon- Observational Studies Showing Relationship Between Thyroid Function and Outcome in HF Patients Author/Year Population* Patients, n Male, n Age, y NYHA Class Adopted Parameter Follow-Up Outcome Hamilton et al,22 1990 Ischemic and nonischemic congestive advanced HF 84 70 17–71† Not reported FT3 index/rT3 ratio 7.3Ϯ6.6‡ mo FT3 index/rT3 ratio Ͼ4: survival 100% Opasich et al,39 1996 Ischemic and nonischemic HF 199 Kozdag et al,40 2005 Ischemic and non ischemic DCM 111 Ischemic and non ischemic DCM 281 Pingitore et al,20 2005 FT3 index/rT3 ratio Յ4: survival 37% 171 51.6Ϯ0.6§ I–IV TT3 417Ϯ259§ d Normal TT3: survival 79% Low TT3: survival 52% 76 62Ϯ12‡ III–IV FT3/FT4 Ratio 12Ϯ8‡ mo FT3/FT4 ratio Ͼ1.7: survival specificity 71% FT3/FT4 ratio Յ1.7: survival sensitivity 100% 207 70Ϯ10‡ I–IV TT3 FT3 LVEF 12Ϯ7‡ mo Normal TT3 and LVEF Ͼ20%: survival 90% Normal TT3 and LVEF Ͻ20%: survival 83% Low TT3 and LVEF Ͼ20%: survival 73% Low TT3 and LVEF Ͻ20%: survival 61% Passino et al,41 2009 Ischemic and nonischemic HF 442 331 65Ϯ12‡ I–IV FT3/BNP 36 mo (median) Low BNP/normal FT3: survival 84% Low FT3/low BNP: survival 69% High BNP/normal FT3: survival 60% High BNP/low FT3: survival 28% NYHA indicates New York Heart Association; rT3, reverse T3; DCM, dilated cardiomyopathy; LVEF, LV ejection fraction; and BNP, brain natriuretic peptide *As defined by author †Range ‡MeanϮSD §MeanϮSE Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 388 Circulation July 27, 2010 strated the presence of low-T3 syndrome in rats after MI T3 treatment improved ejection fraction and normalized some of the changes in gene expression In another study,47 T4 treatment of rats with MI led to a modest improvement in heart function Henderson et al48 demonstrated normal serum T4 levels but a sustained reduction in serum T3 levels to weeks after MI in rats T3 treatment resulted in improved systolic function and a trend for improved diastolic function A study by Olivares et al3 provided more insight into TH impairment in MI After MI was produced in rats, there was a pronounced upregulation of D3 Serum T3 levels did not normalize for months Combined with reduced muscle D2 activity, this may provide an additional mechanism for the reduction of plasma T3 levels that is typically seen after MI T3 treatment of rats with MI led to a decrease in DNA laddering and terminal deoxynucleotidyl transferase dUTP nick-end labeling in the border zone, suggesting a potential protective role.49 T3 can also prevent remodeling by reducing apoptosis at the early phase of ischemia/reperfusion.50 Upregulation of D3 may be a generalized response to cardiac injury since Wassen et al4 have also shown D3 activation in pulmonary hypertension The increase in D3 was specific to the overloaded right ventricle and associated with a reduction of both local T3 content and T3-dependent gene transcription.5 It is likely that reexpression of the fetal gene program in the overloaded ventricle, a common feature of cardiac disease, is enhanced by low tissue TH levels Pantos and colleagues51–55 have published numerous animal studies on the effects of THs on the heart, particularly during ischemia or MI They have shown that short- and long-term T3ϩT4 treatment of rats with MI leads to improved LV function and remodeling.53,54 However, remodeling data were limited to echocardiographs and measurement of infarct size with no tissue structure analyses of spared myocardium Importantly, the Pantos group has not observed any TH treatment–related changes in infarct scar remodeling Because interventions affecting post-MI scar remodeling may lead to cardiac aneurism or rupture and THs are known to have antifibrotic effects, it is reassuring to know that TH treatment is not likely to promote such changes It is interesting to note that T3 and/or T4 replacement therapy has never been tested in humans after MI despite a clear association between low thyroid function and poor prognosis after MI and many animal studies showing similar changes and improvement with TH treatment At present, the issue of using T3, T4, or their combination has not been completely resolved but may depend on specific clinical situations For instance, it seems logical that T4 treatment may work better in the presence of primary hypothyroidism but not in the presence of impaired peripheral conversion of T4 to T3, when T3 seems to be more useful When considering the large number of patients with primary scHypo and the number of patients with heart disease, it is remarkable that only a few animal studies have investigated the combined effects of these conditions We confirmed the presence of scHypo (increased TSH, normal T3 and T4) in BIO-TO2 cardiomyopathic hamsters.56,57 Treatment of TO2 hamsters with a therapeutic dose of T3ϩT4 from to months of age prevented progression of fibronecrosis and further loss of cardiac myocytes and attenuated progressive LV dilatation and dysfunction Resting and maximum (adenosine) coronary blood flow was significantly reduced in both 4- and 6-month-old TO2 hamsters T3ϩT4 treatment of TO2 hamsters normalized resting and maximum blood flow This was the first study to demonstrate potential benefits of TH treatment of scHypo in an animal model of HF.57 It is not known at present if long-term TH treatment of TO2 hamsters will reduce mortality Our studies with TO2 hamsters raise the possibility that patients with similar cardiac conditions may benefit from TH treatment A recent rat study also demonstrated that serum TH levels may be normal when cardiac tissue levels are significantly depressed.58 Cardiac tissue TH levels were a more reliable indicator of LV function than serum hormone levels This raises an important question: How much ventricular dysfunction in cardiac patients who are diagnosed as “euthyroid” is actually due to low tissue hormone levels? Thyroid dysfunction at the tissue level may be exacerbated by downregulation of thyroid nuclear receptors, known to occur in HF.59 Cardiac Remodeling and the Effect of THs Although much of the work on HF has focused largely on improving contractility and relaxation without inducing an increase in heart rate, new evidence suggests that beneficial effects on myocardial tissue remodeling could be a more important target To understand and fully appreciate the effects of THs on myocyte remodeling, a brief overview of myocyte remodeling is helpful Because changes in wall stress are directly proportional to chamber diameter and inversely proportional to wall thickness, it seems plausible that changes in myocyte length and width are likely to play a key role in pathological alterations in chamber diameter and wall thickness, respectively After extensively characterizing and implementing a precise method to measure myocyte size,60 we subsequently documented patterns of myocyte remodeling in many mammalian species during physiological and pathological cardiac growth (see reviews61,62) We demonstrated that pressure overload leads to an increase in myocyte cross-sectional area (CSA) and volume overload leads to proportional growth of myocyte length and width (Figure 261,62) Regardless of the starting point (normal CSA or increased CSA with the presence of hypertension), progression to dilated failure is associated with only cell lengthening from series addition of sarcomeres This is the case in dilation of the noninfarcted myocardium after MI,63,64 idiopathic dilated cardiomyopathy,62 and hypertension associated with dilated failure (Figure 2).65 Cumulatively, our remodeling data suggest that the cellular defect in progression to dilated failure is related to the inability of the myocytes to properly regulate CSA The absence of an increase in CSA as myocytes lengthen leads to a vicious cycle of progressively increasing wall stress, impaired coronary blood flow, and increased stiffness from collagen accumulation in HF Induction of hyperthyroidism in normal rats leads to balanced growth of myocyte length and width,66,67 a pattern similar to that of normal physiological growth.68 Hypothyroidism induced by propylthiouracil in rats leads to cardiac atrophy caused by a reduction in myocyte CSA initially.69 Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 Gerdes and Iervasi Thyroid Treatment of Heart Failure 389 Figure Changes in myocyte shape with pressure and volume overload (reprinted from Gerdes61 with permission of the publisher Copyright © 1992, Elsevier) and progression to HF (reprinted from Gerdes62 with permission of the publisher Copyright © 2002, Elsevier) CSA indicates crosssectional area; L, myocyte length; and W, myocyte width However, long-term hypothyroidism leads to induction of cell lengthening from series sarcomere formation.2 Series addition of sarcomeres is a unique feature of dilated HF and is reversed in myocytes from HF patients after unloading as a result of implantation of a LV assist device.70 So, LV unloading caused by hypothyroidism leads to an unexpected change in myocyte shape typical of HF rather than mechanical unloading We investigated the effects of T3ϩT4 on LV chamber and myocyte remodeling in aging spontaneously hypertensive heart failure rats approaching dilated HF.71 There was a dose-related improvement in the ratio of chamber diameter to wall thickness that normalized systolic wall stress despite the presence of sustained hypertension This alteration in chamber anatomy resulted from a specific change in myocyte shape, namely a reduction in myocyte major diameter (axis runs in a circumferential direction correlating with chamber dimension) and an increase in myocyte minor diameter (axis runs in a transmural or wall thickening dimension).71,72 Preliminary results from T3-treated rats after MI also suggest beneficial changes in myocyte shape (A.M.G., unpublished observation, 2010) Cumulatively, our studies showing improved myocyte shape with TH treatment of various animal models of HF suggest that TH plays an important role in the regulation of myocyte shape in heart disease In particular, THs appear to play a key role in the proper regulation of myocyte transverse shape and hence wall stress It is possible that impaired transverse growth during progression to dilated HF is due to low thyroid function at the tissue level Our knowledge of the molecular regulation of cardiac myocyte shape is slowly evolving Of note, a vast array of complex protein interactions in mechanical stress sensors has been found in many regions of cardiac myocytes, including costameres, intercalated disks, and caveolae-like domains.73 To the best of our knowledge, insertion of series sarcomeres has never been observed in adult heart In vitro work by Yu and Russell,74 however, suggests that new series sarcomeres are formed throughout the cell length Very little is known about the regulation of myocyte CSA Of interest is the transmission of lateral force during myocyte contraction via cytoskeletal linkage from the sarcolemma to the nucleus.75 A complex array of structural and signaling proteins is located in this transverse network involving the sarcolemma, cos- tameres, and Z disks It is possible that this lateral network is a key regulator of myocyte CSA This was suggested by studies showing a critical role for the cytoskeletal protein melusin, which interacts with the ␤1-integrin in the costameric region of cardiac myocytes.76,77 Melusin is upregulated in early hypertension (CSA growth period) and downregulated with progression to dilated HF (cell-lengthening phase).77 Melusin knockout mice showed excessive dilatation and impaired growth of myocyte CSA after aortic constriction, whereas melusin overexpression promoted wall thickening and prevented dilated HF after aortic constriction.76,77 Like THs, melusin protects from fibrosis and apoptosis and stimulates Akt signaling THs increase NO expression, and NO is known to increase expression of costameric proteins.78 T3 has also been shown to trigger Akt-dependent changes in titin isoform transitions.79 These examples are given simply to show how THs could affect mechanosensors and myocyte shape Clearly, more work is needed to demonstrate specific mechanisms and causality TH Treatment in HF A prolonged controversy has developed over the issue of TH treatment in cardiac patients, with data limited to only a few studies.80 – 86 A strong argument in favor of TH treatment in HF is that the failing heart has alterations in gene expression similar to that found in hypothyroidism,87,88 with all abnormalities being reversible with TH substitutive treatment An unresolved question, however, is related to the meaning of low FT3 in the background of normal levels of TSH and FT4, which is observed in the majority of nonthyroidal illness patients Under these circumstances, TH action in peripheral target tissues such as the heart is poorly understood A major limitation involves the assessment of tissue TH status in peripheral tissues based on hormonal blood-borne data only Aside from the central issue of dosage, timing for initiating and discontinuing TH treatment in scHypo patients with HF is not clear A good biomarker of intracardiac TH signaling would be helpful but has not been identified In the absence of such a marker, a rational, cautious therapeutic approach might be to restore and maintain over time biochemical euthyroidism as documented by normal circulating levels of TSH, FT4, and FT3 Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 390 Circulation July 27, 2010 Table TH and TH Analog DITPA Treatment in Patients With HF Author/ Year Study Design Population Patients, n Age*, y NYHA LVEF, % Intervention Main Findings Heart Rate Side Effects Moruzzi et al,85 1994 Randomized (1:1), placebo controlled Nonischemic HF 10 47–78 II–III 27Ϯ8 T4 100 ␮g/d for wk OS SVR (dobutamine test), CO (dobutamine test), O2 consumption, exercise tolerance, resting LVEF Unchanged No Moruzzi et al,91 1996 Randomized (1:1), placebo controlled Nonischemic HF 10 51–70 II–IV 29Ϯ6 T4 100 ␮g/d for mo OS Cardiac performance at rest, exercise, and dobutamine test; LVEDD; SVR Unchanged No Hamilton et al,84 1998 Uncontrolled Ischemic, nonischemic HF 23 50 III–IV 22Ϯ1 T3 cumulative dose 0.15–2.7 ␮g/kg bolusϩcontinuous infusion (6–12 h) SVR, CO Unchanged No Malik et al,92 1999 Uncontrolled Systolic HF (cardiogenic shock) 10 37–65 Not available T4 20 ␮g/h bolusϩcontinuous infusion (36 h) CI, PCWP and MAP Unchanged No Iervasi et al,86 2001 Uncontrolled Ischemic, nonischemic HF 64Ϯ8 III–IV 24Ϯ3 T3 initial dose 20 ␮g/m2bs per d, continuous infusion (4 d) SVR, CO, UO Unchanged No Pingitore et al,93 2008 Randomized (1:1), placebo controlled Ischemic, nonischemic HF 20 64–77 I–III 25 18–32 T3 initial dose 20 ␮g/m2bs per day, continuous infusion (3 d) LFSV, LVEDV, NT–proBNP, noradrenaline, aldosterone Reduced No Goldman et al,94 2009 Randomized (2:1), placebo-controlled Ischemic, nonischemic HF 86 65.6Ϯ11 (T) 67.3Ϯ10.3 (P) II–IV 28Ϯ6.8 (T) 28Ϯ6 (P) DITPA twice daily, 90-mg increments (every wk) to maximum 360 mg CI, SVR, lipoproteins and cholesterol Increased Poorly tolerated, weight loss, fatigue, GI complaints NYHA indicates New York Heart Association; DCM, dilated cardiomyopathy; LVEF, LV ejection fraction; SVR, systemic vascular resistances; CO, cardiac output; CI, cardiac index; UO, urinary output; LVEDD, LV end-diastolic diameter; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; LVSV, LV stroke volume; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; T, Treated; P, Placebo; GI, gastrointestinal; m2bs, m2 body surface; and OS, oral administration *Age reported as range, mean, or meanϩSD TH-based novel therapeutic options could find suitable application not only at early but also at end stages of HF Treatment with physiological doses of T3 is able to restore the expression of Ca(2ϩ) cycling and handling proteins and contractile function of cardiac myocytes in an animal model of chronic cardiac unloading (a condition similar to that in patients with end-stage HF after LV assist device implantation).89 Tissue-engineered heart muscle (also called cardioids) is a fascinating alternative treatment modality for end-stage congestive HF T3 stimulation is able to promote the selforganization of primary neonatal cardiac cells into a contractile tissue construct An increased rate of contraction and relaxation in response to T3 stimulation is observed with parallel changes in the gene expression of SERCA2, phospholamban, and myosin heavy chains.90 A number of preclinical studies have tested L-T4, L-T3, or TH analog diiodothyropropionic acid (DITPA) replacement therapy in patients with HF (Table 284 – 86,91–94) Synthetic L-T3 or L-T4 improved LV function consisting of enhanced resting cardiac output and exercise capacity and reduced systemic vascular resistance However, the protocols used for T3 administration in HF patients were much different Independently of the adopted L-T3 regimen and different from DITPA, T3 was well tolerated, and undesirable effects consisting of arrhythmias, myocardial ischemia, or hemody- namic instability were not documented In a clinical study from our group, improvement in cardiac performance induced by T3 did not correspond to increased myocardial oxygen consumption as indirectly estimated by calculation of the rate-pressure product and total cardiac work.93 Importantly, the benefit of T3 infusion on cardiac function paralleled deactivation of the neuroendocrine profile In the abovementioned study,93,95 the effects of TH replacement therapy on cardiac function and morphology were assessed by cardiac magnetic resonance, a noninvasive and nonionizing technique currently considered the gold standard approach to assess LV volumes and regional global function The high quality of imaging and the 3-dimensional approach of cardiac magnetic resonance allow assessment of LV postischemic remodeling accurately with high reproducibility, enabling smaller sample sizes to reach statistical significance.96,97 It is worth noting here that a phase II, randomized, double-blind, placebo-controlled clinical trial investigating the effects of T3 treatment in patients with MI was recently initiated by Dr Iervasi (Thyroid Hormone Replacement Therapy in ST Elevation MI [THiRST]) Conclusions A growing body of evidence suggests that TH dysfunction may play an important role in the progression to dilated HF Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 Gerdes and Iervasi Therapeutic use of THs in HF has not been adequately studied Until now, most studies have targeted improvement in LV function THs also produce remarkable improvements in remodeling, including beneficial changes in myocyte shape, microcirculation, and collagen Clearly, more studies are needed to explore the full potential of the therapeutic use of THs in treating and/or preventing HF Disclosures None References Klein I, Ojamaa K Thyroid hormone and the cardiovascular system N Engl J Med 2001;344:501–509 Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction Circulation 2005;112:3122–3130 Olivares EL, Marassi MP, Fortunato RS, da Silva AC, Costa-e-Sousa RH, Araujo IG, Mattos EC, Masuda MO, Mulcahey MA, Huang SA, Bianco AC, Carvalho DP Thyroid function disturbance and type iodothyronine deiodinase induction after myocardial infarction in rats a time course study Endocrinology 2007;148:4786 – 4792 Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, Simonides WS Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure Endocrinology 2002;143:2812–2815 Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, Wassen FW, Crescenzi A, da-Silva WS, Harney J, Engel FB, Obregon MJ, Larsen PR, Bianco AC, Huang SA Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats J Clin Invest 2008;118:975–983 Pol CJ, Muller A, Simonides WS Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem? Heart Fail Rev 2010;15:133–142 Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R Thyroidal and peripheral production of 3,5,3Ј-triiodothyronine in humans by multicompartmental analysis Am J Physiol 1990;258:E715–E726 Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases Endocr Rev 2002;23:38 – 89 Heuer H, Visser TJ Minireview: pathophysiological importance of thyroid hormone transporters Endocrinology 2009;150:1078 –1083 10 Dillmann W Cardiac hypertrophy and thyroid hormone signaling Heart Fail Rev 2010;15:125–132 11 Katzeff HL, Powell SR, Ojamaa K Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3 Am J Physiol 1997;273:E951–E956 12 Aber CP, Thompson GS Factors associated with cardiac enlargement in myxoedema Br Heart J 1963;25:421– 424 13 Kahaly GJ Cardiovascular and atherogenic aspects of subclinical hypothyroidism Thyroid 2000;10:665– 679 14 Chen WJ, Lin KH, Lee YS Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor Mol Cell Endocrinol 2000;162:45–55 15 Yao J, Eghbali M Decreased collagen gene expression and absence of fibrosis in thyroid hormone-induced myocardial hypertrophy: response of cardiac fibroblasts to thyroid hormone in vitro Circ Res 1992;71: 831– 839 16 Biondi B, Cooper DS The clinical significance of subclinical thyroid dysfunction Endocr Rev 2008;29:76 –131 17 Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ Subclinical thyroid disease: scientific review and guidelines for diagnosis and management JAMA 2004;291:228 –238 18 Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L’Abbate A, Pingitore A Association between increased mortality and mild thyroid dysfunction in cardiac patients Arch Intern Med 2007;167:1526 –1532 19 Friberg L, Drvota V, Bjelak AH, Eggertsen G, Ahnve S Association between increased levels of reverse triiodothyronine and mortality after acute myocardial infarction Am J Med 2001;111:699 –703 Thyroid Treatment of Heart Failure 391 20 Pingitore A, Landi P, Taddei MC, Ripoli A, L’Abbate A, Iervasi G Triiodothyronine levels for risk stratification of patients with chronic heart failure Am J Med 2005;118:132–136 21 Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L’Abbate A, Donato L Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease Circulation 2003;107:708 –713 22 Hamilton MA, Stevenson LW, Luu M, Walden JA Altered thyroid hormone metabolism in advanced heart failure J Am Coll Cardiol 1990;16:91–95 23 Biondi B, Palmieri EA, Lombardi G, Fazio S Effects of subclinical thyroid dysfunction on the heart Ann Intern Med 2002;137:904 –914 24 Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study Ann Intern Med 2000;132:270 –278 25 Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years Clin Endocrinol (Oxf) 2004;61:232–238 26 Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial J Clin Endocrinol Metab 2007;92:1715–1723 27 Asvold BO, Bjoro T, Nilsen TI, Gunnell D, Vatten LJ Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study Arch Intern Med 2008;168:855– 860 28 Silva-Tinoco R, Castillo-Martinez L, Orea-Tejeda A, Orozco-Gutierrez JJ, Vazquez-Diaz O, Montano-Hernandez P, Flores-Rebollar A, RezaAlbarran A Developing thyroid disorders is associated with poor prognosis factors in patient with stable chronic heart failure Int J Cardiol 2009 29 Iacoviello M, Guida P, Guastamacchia E, Triggiani V, Forleo C, Catanzaro R, Cicala M, Basile M, Sorrentino S, Favale S Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients Curr Pharm Des 2008;14:2686 –2692 30 Vanderpump MP How should we manage patients with mildly increased serum thyrotrophin concentrations? Clin Endocrinol (Oxf) 2009 31 Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, Bauer DC Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death Arch Intern Med 2005; 165:2460 –2466 32 Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, Ladenson PW, Vittinghoff E, Gottdiener JS, Newman AB Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure: the Cardiovascular Health Study J Am Coll Cardiol 2008;52:1152–1159 33 Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab 2002;87:489 – 499 34 Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism J Clin Endocrinol Metab 2004;89:3365–3370 35 Asvold BO, Vatten LJ, Nilsen TI, Bjoro T The association between TSH within the reference range and serum lipid concentrations in a population-based study: the HUNT Study Eur J Endocrinol 2007;156: 181–186 36 Coceani M, Iervasi G, Pingitore A, Carpeggiani C, L’Abbate A Thyroid hormone and coronary artery disease: from clinical correlations to prognostic implications Clin Cardiol 2009;32:380 –385 37 Portman MA Thyroid hormone regulation of heart metabolism Thyroid 2008;18:217–225 38 Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging J Clin Endocrinol Metab 2000;85: 1822–1827 39 Opasich C, Pacini F, Ambrosino N, Riccardi PG, Febo O, Ferrari R, Cobelli F, Tavazzi L Sick euthyroid syndrome in patients with moderateto-severe chronic heart failure Eur Heart J 1996;17:1860 –1866 40 Kozdag G, Ural D, Vural A, Agacdiken A, Kahraman G, Sahin T, Ural E, Komsuoglu B Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy Eur J Heart Fail 2005;7:113–118 Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 392 Circulation July 27, 2010 41 Passino C, Pingitore A, Landi P, Fontana M, Zyw L, Clerico A, Emdin M, Iervasi G Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure J Card Fail 2009;15:35– 40 42 Schmidt-Ott UM, Ascheim DD Thyroid hormone and heart failure Curr Heart Fail Rep 2006;3:114 –119 43 Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Karatasakis G, Athanassopoulos G, Mavrogeni S, Manginas A, Cokkinos DV Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications Eur J Endocrinol 2007;157:515–520 44 Friberg L, Werner S, Eggertsen G, Ahnve S Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 2002;162:1388 –1394 45 Karlsberg RP, Friscia DA, Aronow WS, Sekhon SS Deleterious influence of hypothyroidism on evolving myocardial infarction in conscious dogs J Clin Invest 1981;67:1024 –1034 46 Ojamaa K, Kenessey A, Shenoy R, Klein I Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat Am J Physiol Endocrinol Metab 2000;279:E1319 –E1324 47 Gay RG, Graham S, Aguirre M, Goldman S, Morkin E Effects of 10- to 12-day treatment with L-thyroxine in rats with myocardial infarction Am J Physiol 1988;255:H801–H806 48 Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure Circ Heart Fail 2009;2:243–252 49 Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats J Mol Cell Cardiol 2008;44:180 –187 50 Pantos C, Mourouzis I, Saranteas T, Clave G, Ligeret H, NoackFraissignes P, Renard PY, Massonneau M, Perimenis P, Spanou D, Kostopanagiotou G, Cokkinos DV Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: a new therapeutic approach to support hemodynamics in the setting of ischaemiareperfusion? Basic Res Cardiol 2009;104:69 –77 51 Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart Mol Cell Biochem 2003;242:173–180 52 Pantos C, Mourouzis I, Cokkinos DV Rebuilding the post-infarcted myocardium by activating “physiologic” hypertrophic signaling pathways: the thyroid hormone paradigm Heart Fail Rev 2010;15: 143–154 53 Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, Panagiotou M, Cokkinos DV Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats Eur J Cardiothorac Surg 2007;32:333–339 54 Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats Basic Res Cardiol 2008;103:308 –318 55 Pantos CI, Malliopoulou VA, Mourouzis IS, Karamanoli EP, Paizis IA, Steimberg N, Varonos DD, Cokkinos DV Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning Thyroid 2002;12:325–329 56 Kuzman JA, Tang Y, Vogelsang KA, Said S, Anderson BE, Morkin E, Gerdes AM Thyroid hormone analog, diiodothyropropionic acid (DITPA), exerts beneficial effects on chamber and cellular remodeling in cardiomyopathic hamsters Can J Physiol Pharmacol 2007;85:311–318 57 Khalife WI, Tang YD, Kuzman JA, Thomas TA, Anderson BE, Said S, Tille P, Schlenker EH, Gerdes AM Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy Am J Physiol Heart Circ Physiol 2005;289:H2409 –H2415 58 Liu Y, Redetzke RA, Said S, Pottala JV, de Escobar GM, Gerdes AM Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism Am J Physiol Heart Circ Physiol 2008;294:H2137–H2143 59 Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy Circ Res 2001;89:591–598 60 Gerdes AM, Moore JA, Hines JM, Kirkland PA, Bishop SP Regional differences in myocyte size in normal rat heart Anat Rec 1986;215: 420 – 426 61 Gerdes AM The use of isolated myocytes to evaluate myocardial remodeling Trends Cardiovasc Med 1992;2:152–155 62 Gerdes AM Cardiac myocyte remodeling in hypertrophy and progression to failure J Card Fail 2002;8:S264 –S268 63 Zimmer HG, Gerdes AM, Lortet S, Mall G Changes in heart function and cardiac cell size in rats with chronic myocardial infarction J Mol Cell Cardiol 1990;22:1231–1243 64 Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, Malec KB, McKeown PP, Schocken DD Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy Circulation 1992;86:426 – 430 65 Gerdes AM, Onodera T, Wang X, McCune SA Myocyte remodeling during the progression to failure in rats with hypertension Hypertension 1996;28:609 – 614 66 Gerdes AM, Moore JA, Hines JM Regional changes in myocyte size and number in propranolol-treated hyperthyroid rats Lab Invest 1987;57: 708 –713 67 Campbell SE, Gerdes AM Regional changes in myocyte size during the reversal of thyroid-induced cardiac hypertrophy J Mol Cell Cardiol 1988;20:379 –387 68 Bai SL, Campbell SE, Moore JA, Morales MC, Gerdes AM Influence of age, growth, and sex on cardiac myocyte size and number in rats Anat Rec 1990;226:207–212 69 Liu Z, Gerdes AM Influence of hypothyroidism and the reversal of hypothyroidism on hemodynamics and cell size in the adult rat heart J Mol Cell Cardiol 1990;22:1339 –1348 70 Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB Regression of cellular hypertrophy after left ventricular assist device support Circulation 1998;98:656 – 662 71 Thomas TA, Kuzman JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, Gerdes AM Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure Am J Physiol Heart Circ Physiol 2005;288:H2118 –H2122 72 Gerdes AM, Kellerman SE, Malec KB, Schocken DD Transverse shape characteristics of cardiac myocytes from rats and humans Cardioscience 1994;5:31–36 73 Hoshijima M Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures Am J Physiol Heart Circ Physiol 2006;290:H1313–H1325 74 Yu JG, Russell B Cardiomyocyte remodeling and sarcomere addition after uniaxial static strain in vitro J Histochem Cytochem 2005;53: 839 – 844 75 Ervasti JM Costameres: the Achilles’ heel of Herculean muscle J Biol Chem 2003;278:13591–13594 76 Brancaccio M, Fratta L, Notte A, Hirsch E, Poulet R, Guazzone S, De Acetis M, Vecchione C, Marino G, Altruda F, Silengo L, Tarone G, Lembo G Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload Nat Med 2003;9:68 –75 77 De Acetis M, Notte A, Accornero F, Selvetella G, Brancaccio M, Vecchione C, Sbroggio M, Collino F, Pacchioni B, Lanfranchi G, Aretini A, Ferretti R, Maffei A, Altruda F, Silengo L, Tarone G, Lembo G Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload Circ Res 2005;96:1087–1094 78 Chaubourt E, Voisin V, Fossier P, Baux G, Israel M, De La Porte S Muscular nitric oxide synthase (muNOS) and utrophin J Physiol Paris 2002;96:43–52 79 Kruger M, Sachse C, Zimmermann WH, Eschenhagen T, Klede S, Linke WA Thyroid hormone regulates developmental titin isoform transitions via the phosphatidylinositol-3-kinase/AKT pathway Circ Res 2008;102: 439 – 447 80 Klemperer JD, Klein I, Gomez M, Helm RE, Ojamaa K, Thomas SJ, Isom OW, Krieger K Thyroid hormone treatment after coronary-artery bypass surgery N Engl J Med 1995;333:1522–1527 81 Ranasinghe AM, Quinn DW, Pagano D, Edwards N, Faroqui M, Graham TR, Keogh BE, Mascaro J, Riddington DW, Rooney SJ, Townend JN, Wilson IC, Bonser RS Glucose-insulin-potassium and tri-iodothyronine individually improve hemodynamic performance and are associated with reduced troponin I release after on-pump coronary artery bypass grafting Circulation 2006;114(suppl):I-245–I-250 82 Portman MA, Fearneyhough C, Ning XH, Duncan BW, Rosenthal GL, Lupinetti FM Triiodothyronine repletion in infants during cardiopulmo- Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 Gerdes and Iervasi 83 84 85 86 87 88 89 90 91 nary bypass for congenital heart disease J Thorac Cardiovasc Surg 2000;120:604 – 608 Novitzky D Novel actions of thyroid hormone: the role of triiodothyronine in cardiac transplantation Thyroid 1996;6:531–536 Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure Am J Cardiol 1998;81:443– 447 Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy Am J Cardiol 1994;73:374 –378 Iervasi G, Emdin M, Colzani RMP, Placidi S, Sabatino L, Scarlattini M, Formichi B Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome In: Kimchi A., ed Second International Congress on Heart Disease - New Trends in Research, Diagnosis and Treatment Englewood, NJ: Medimond Medical Publications; 2001:549 –553 Ladenson PW, Sherman SI, Baughman KL, Ray PE, Feldman AM Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism Proc Natl Acad Sci U S A 1992;89:5251–5255 Klein I, Danzi S Thyroid hormone treatment to mend a broken heart J Clin Endocrinol Metab 2008;93:1172–1174 Ito K, Kagaya Y, Shimokawa H Thyroid hormone and chronically unloaded hearts Vascul Pharmacol 2010;52:138 –141 Khait L, Birla RK Effect of thyroid hormone on the contractility of self-organized heart muscle In Vitro Cell Dev Biol Anim 2008;44: 204 –213 Moruzzi P, Doria E, Agostoni PG Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy Am J Med 1996;101:461– 467 Thyroid Treatment of Heart Failure 393 92 Malik FS, Mehra MR, Uber PA, Park MH, Scott RL, Van Meter CH Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock J Card Fail 1999;5:31–37 93 Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L’Abbate A, Mariotti R, Iervasi G Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study J Clin Endocrinol Metab 2008;93:1351–1358 94 Goldman S, McCarren M, Morkin E, Ladenson PW, Edson R, Warren S, Ohm J, Thai H, Churby L, Barnhill J, O’Brien T, Anand I, Warner A, Hattler B, Dunlap M, Erikson J, Shih MC, Lavori P DITPA (3,5diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study Circulation 2009;119:3093–3100 95 Ripoli A, Pingitore A, Favilli B, Bottoni A, Turchi S, Osman NF, De Marchi D, Lombardi M, L’Abbate A, Iervasi G Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study J Am Coll Cardiol 2005;45:439 – 445 96 Westenberg JJ, van der Geest RJ, Lamb HJ, Versteegh MI, Braun J, Doornbos J, de Roos A, van der Wall EE, Dion RA, Reiber JH, Bax JJ MRI to evaluate left atrial and ventricular reverse remodeling after restrictive mitral annuloplasty in dilated cardiomyopathy Circulation 2005;112(suppl):I-437–I-442 97 Rajappan K, Bellenger NG, Anderson L, Pennell DJ The role of cardiovascular magnetic resonance in heart failure Eur J Heart Fail 2000;2:241–252 KEY WORDS: angiogenesis Ⅲ thyroid hormones Ⅲ heart failure Ⅲ myocardial infarction Ⅲ remodeling Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 Thyroid Replacement Therapy and Heart Failure Anthony Martin Gerdes and Giorgio Iervasi Circulation 2010;122:385-393 doi: 10.1161/CIRCULATIONAHA.109.917922 Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2010 American Heart Association, Inc All rights reserved Print ISSN: 0009-7322 Online ISSN: 1524-4539 The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circ.ahajournals.org/content/122/4/385 Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services Further information about this process is available in the Permissions and Rights Question and Answer document Reprints: Information about reprints can be found online at: http://www.lww.com/reprints Subscriptions: Information about subscribing to Circulation is online at: http://circ.ahajournals.org//subscriptions/ Downloaded from http://circ.ahajournals.org/ by guest on January 18, 2015 ... resonance in heart failure Eur J Heart Fail 2000;2:241–252 KEY WORDS: angiogenesis Ⅲ thyroid hormones Ⅲ heart failure Ⅲ myocardial infarction Ⅲ remodeling Downloaded from http://circ.ahajournals.org/... Influence of hypothyroidism and the reversal of hypothyroidism on hemodynamics and cell size in the adult rat heart J Mol Cell Cardiol 1990;22:1339 –1348 70 Zafeiridis A, Jeevanandam V, Houser... JA, Anderson BE, Andersen SM, Schlenker EH, Holder MS, Gerdes AM Thyroid hormones induce unique and potentially beneficial changes in cardiac myocyte shape in hypertensive rats near heart failure